Kantonsspital St.Gallen

XATOA – Xarelto + Acetylsalicylic Acid: Treatment

Hans Rickli, Michaela Gemperle & Karin Fink

abstract The study aims to collect real-world data on treatment
patterns and decision points for treatment in patients with
coronary artery disease (CAD) or symptomatic peripheral
artery disease (PAD) treated with rivaroxaban 2.5 mg[BID]
for the prevention of atherothrombotic events in adult
patients at high risk of ischaemic events and to describe
outcomes of an antithrombotic regime based on dual
pathway inhibition (vascular dose of rivaroxaban 2.5 mg
[BID] plus low-dose ASA [OD]) across the broad range of
patient risk profiles encountered in routine clinical practice.
The primary objective in this study is:
• to describe treatment patterns in CAD or PAD
patients treated with rivaroxaban 2.5 mg [BID] plus
ASA 75-100 mg [OD] in routine clinical practice
project homepage http://https://clinicaltrials.gov/ct2/show/NCT03746275
project partner BAYER
type of project clinical studies
status completed
start of project 2019
end of project 2021
study design Observational Model: Cohort
Time Perspective: Prospective
responsible person Prof. Dr. Hans Rickli